TY - JOUR
T1 - Kidney function decline among black patients with sickle cell trait and sickle cell disease
T2 - An observational cohort study
AU - Olaniran, Kabir O.
AU - Allegretti, Andrew S.
AU - Zhao, Sophia H.
AU - Achebe, Maureen M.
AU - Eneanya, Nwamaka D.
AU - Thadhani, Ravi I.
AU - Nigwekar, Sagar U.
AU - Kalim, Sahir
N1 - Funding Information:
Dr. Olaniran is supported by the Ben J. Lipps Research Fellowship Award of the American Society of Nephrology. Dr. Allegretti is supported by the American Heart Association Career Development Award 18CDA34110131. Dr. Eneanya is supported by National Institutes of Health (NIH) grant K23DK114526-01. Dr. Thadhani is supported by NIH grant R01DK094486-06. Dr. Nigwekar is supported by the American Heart Association National Center for Research Program Winter 2015 Fellow-to-Faculty Transition Award 15FTF25980003, and by the Harvard Catalyst, The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH), KL2/Catalyst Medical Research Investigator Training Award TR001100 (an appointed KL2 award). Dr. Kalim is supported by NIH award K23DK106479.
Publisher Copyright:
© 2020 by the American Society of Nephrology.
PY - 2020
Y1 - 2020
N2 - Background Sickle cell trait and sickle cell disease are thought to be independent risk factors for CKD, but the trajectory and predictors of kidney function decline in patients with these phenotypes are not well understood. Methods Our multicenter, observational study used registry data (collected January 2005 through June 2018) and included adult black patients with sickle cell trait or disease (exposures) or normal hemoglobin phenotype (reference) status (ascertained by electrophoresis) and at least 1 year of follow-up and three eGFR values.We used linearmixedmodels to evaluate the difference in themean change in eGFR per year. Results We identified 1251 patients with sickle cell trait, 230 with sickle cell disease, and 8729 reference patients, with a median follow-up of 8 years. After adjustment, eGFR declined significantly faster in patients with sickle cell trait or sickle cell disease compared with reference patients; it also declined significantly faster in patients with sickle cell disease than in patients with sickle cell trait. Male sex, diabetes mellitus, and baseline eGFR $90 ml/min per 1.73 m2 were associated with faster eGFR decline for both phenotypes. In sickle cell trait, low hemoglobin S and elevated hemoglobin A were associated with faster eGFR decline, but elevated hemoglobins F and A2 were renoprotective. Conclusions Sickle cell trait and disease are associated with faster eGFR decline in black patients, with faster decline in sickle cell disease. Lowhemoglobin Swas associated with faster eGFR decline in sickle cell trait but may be confounded by concurrent hemoglobinopathies. Prospective andmechanistic studies are needed to develop best practices to attenuate eGFR decline in such patients.
AB - Background Sickle cell trait and sickle cell disease are thought to be independent risk factors for CKD, but the trajectory and predictors of kidney function decline in patients with these phenotypes are not well understood. Methods Our multicenter, observational study used registry data (collected January 2005 through June 2018) and included adult black patients with sickle cell trait or disease (exposures) or normal hemoglobin phenotype (reference) status (ascertained by electrophoresis) and at least 1 year of follow-up and three eGFR values.We used linearmixedmodels to evaluate the difference in themean change in eGFR per year. Results We identified 1251 patients with sickle cell trait, 230 with sickle cell disease, and 8729 reference patients, with a median follow-up of 8 years. After adjustment, eGFR declined significantly faster in patients with sickle cell trait or sickle cell disease compared with reference patients; it also declined significantly faster in patients with sickle cell disease than in patients with sickle cell trait. Male sex, diabetes mellitus, and baseline eGFR $90 ml/min per 1.73 m2 were associated with faster eGFR decline for both phenotypes. In sickle cell trait, low hemoglobin S and elevated hemoglobin A were associated with faster eGFR decline, but elevated hemoglobins F and A2 were renoprotective. Conclusions Sickle cell trait and disease are associated with faster eGFR decline in black patients, with faster decline in sickle cell disease. Lowhemoglobin Swas associated with faster eGFR decline in sickle cell trait but may be confounded by concurrent hemoglobinopathies. Prospective andmechanistic studies are needed to develop best practices to attenuate eGFR decline in such patients.
UR - http://www.scopus.com/inward/record.url?scp=85078867190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078867190&partnerID=8YFLogxK
U2 - 10.1681/ASN.2019050502
DO - 10.1681/ASN.2019050502
M3 - Article
C2 - 31810990
AN - SCOPUS:85078867190
SN - 1046-6673
VL - 31
SP - 393
EP - 404
JO - Journal of the American Society of Nephrology
JF - Journal of the American Society of Nephrology
IS - 2
ER -